OpenLearning Limited (ASX: OLL) has taken a significant step in its Southeast Asian growth strategy with a five-year, usage-based SaaS agreement with Cebu Institute of Technology University (CIT) in the Philippines. Valued at a minimum of A$340,000 over the term, the deal will see OpenLearning’s AI-powered Learning Management System (LMS) implemented across all faculties and programs at one of the country’s most respected private universities.

In its first reporting season since listing on the ASX in late 2024, Symal Group Limited (ASX: SYL) has made clear strides in delivering its prospectus promises. Most notably, the company has been awarded a $347 million conditional contract for civil works on the Gawara Baya Wind Farm, located in North Queensland on Gugu Badhun Country. This project aligns directly with Australia’s energy transition agenda, aiming to displace 1.3 million tonnes of CO₂ emissions per year.

FOS Capital Limited (ASX: FOS) is a founder-led Australian manufacturer and distributor of commercial, industrial, and architectural lighting solutions. Since listing on the ASX in June 2021, the company has demonstrated consistent growth, underpinned by a clear acquisition strategy and disciplined operational execution.

When it comes to spotting undervalued potential in biotech, I often look for companies that are not only developing novel technologies but also demonstrating clear paths to commercialisation. This month, three small-cap names on the ASX have really caught my attention: Memphasys Limited (ASX: MEM), Control Bionics (ASX: CBL), and dorsaVi Ltd (ASX: DVL). Each is on a very different mission, but all three are making measurable progress—and investors are starting to notice.

LTR Pharma (ASX: LTP) has made impressive strides with the launch of its innovative SPONTAN nasal spray for erectile dysfunction (ED).